A Phase 3 interventional study of Flortaucipir F18 and PET Scan in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 31 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-09-07.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 8th largest by enrollment, is one of 4 that started in 2015, is one of 3 in phase 3, and was the 11th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 4 started in 2015.
This study's enrollment of 156 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 34th largest by enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2015, is one of 24 in phase 3, and was the 57th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Flortaucipir F18 · Procedure: PET Scan
370 megabecquerel (MBq) IV single-dose
Also known as: [F-18]T807, 18F-AV-1451, LY3191748
positron emission tomography (PET) scan
Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score)
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (Braak Stage 0; no NFTs in the brain) to B3 (Braak Stage V/VI; widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
Time frame: at autopsy within 9 months of baseline scan
Primary Outcome 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to high levels of Alzheimer's disease neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain (Hyman et al., Alzheimers Dement. 2012 Jan;8(1):1-13). The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
Time frame: at autopsy within 9 months of baseline scan
Flortaucipir Diagnostic Performance (NFT Score)
Sensitivity and specificity of majority interpretation of AD pattern tau PET scan corresponding to NFT Score of B3. The 95% confidence intervals (CI) provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.
Time frame: at autopsy within 9 months of baseline scan
Flortaucipir Diagnostic Performance (NIA-AA Autopsy Diagnosis)
Sensitivity and specificity of majority interpretation of of AD pattern tau PET scan corresponding to NIA-AA autopsy diagnosis. The 95% CIs provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.
Time frame: at autopsy within 9 months of baseline scan
Inter-Reader Agreement
Fleiss' Kappa statistics were used to assess inter-reader agreement for the diagnostic decisions associated with primary outcome 1. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Results are reported as overall agreement, calculated as proportion of scans where reader pairs agreed, divided by the total number of scans read by each reader pair.
Time frame: baseline scan
Diagnostic Performance of Individual Readers (NFT Score B2-B3 as Truth Positive)
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. For this analysis, B scores of B2-B3 were considered truth positive, and B scores of B0-B1 were considered truth negative.
Time frame: at autopsy within 9 months of baseline scan
Enrollment occurred between October 2015 and June 2018. Enrolled end-of-life subjects (life expectancy less than 6 months) at hospice centers in the US and Australia consented to a flortaucipir PET scan and to brain donation at autopsy.
| Milestone | All Enrolled Cohort |
|---|---|
| Started | 156 |
| Died while on study | 73 |
| Valid autopsy results and pet scan | 67 |
| Completed | 64 |
| Not completed | 92 |
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (Braak Stage 0; no NFTs in the brain) to B3 (Braak Stage V/VI; widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
| percentage of cases correctly identified | Sensitivity of Flortaucipir vs Autopsy NFT Score B3 | Specificity of Flortaucipir vs Autopsy NFT Score <B3 |
|---|---|---|
| Reader 1 | 97.4 (86.8 to 99.5) | 68.0 (48.4 to 82.8) |
| Reader 2 | 92.3 (79.7 to 97.3) | 92.0 (75.0 to 97.8) |
| Reader 3 | 92.3 (79.7 to 97.3) | 88.0 (70.0 to 95.8) |
| Reader 4 | 92.3 (79.7 to 97.3) | 76.0 (56.6 to 88.5) |
| Reader 5 | 100 (91.0 to 100.0) | 52.0 (33.5 to 70.0) |
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to high levels of Alzheimer's disease neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain (Hyman et al., Alzheimers Dement. 2012 Jan;8(1):1-13). The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
| percentage of cases correctly identified | Sensitivity of Flortaucipir vs NIA-AA Autopsy Diagnosis | Specificity of Flortaucipir vs NIA-AA Autopsy Diagnosis |
|---|---|---|
| Reader 1 | 97.5 (87.1 to 99.6) | 65.4 (46.2 to 80.6) |
| Reader 2 | 95.0 (83.5 to 98.6) | 92.3 (75.9 to 97.9) |
| Reader 3 | 95.0 (83.5 to 98.6) | 88.5 (71.0 to 96.0) |
| Reader 4 | 95.0 (83.5 to 98.6) | 76.9 (57.9 to 89.0) |
| Reader 5 | 100 (91.2 to 100.0) | 50.0 (32.1 to 67.9) |
Sensitivity and specificity of majority interpretation of AD pattern tau PET scan corresponding to NFT Score of B3. The 95% confidence intervals (CI) provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.
| percentage of cases correctly identified | Sensitivity of Flortaucipir vs Autopsy NFT Score B3 | Specificity of Flortaucipir vs Autopsy NFT Score <B3 |
|---|---|---|
| Flortaucipir Diagnostic Performance (NFT Score) | 92.3 (79.7 to 97.3) | 80.0 (60.9 to 91.1) |
Sensitivity and specificity of majority interpretation of of AD pattern tau PET scan corresponding to NIA-AA autopsy diagnosis. The 95% CIs provided for specificity and sensitivity were based on the Wilson score method. The hypothesis tested was that majority read results had the lower bound of the 2-sided 95% CI greater than or equal to 55% for both sensitivity and specificity.
| percentage of cases correctly identified | Sensitivity Majority Read NIA-AA Autopsy Diagnosis | Specificity Majority Read NIA-AA Autopsy Diagnosis |
|---|---|---|
| Flortaucipir Diagnostic Performance (NIA-AA Autopsy Diagnosis) | 94.7 (82.7 to 98.5) | 80.8 (62.1 to 91.5) |
Fleiss' Kappa statistics were used to assess inter-reader agreement for the diagnostic decisions associated with primary outcome 1. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Results are reported as overall agreement, calculated as proportion of scans where reader pairs agreed, divided by the total number of scans read by each reader pair.
| proportion of agreed cases | All Cases Read |
|---|---|
| Reader 1 v Reader 2 | 0.79 |
| Reader 1 v Reader 3 | 0.79 |
| Reader 1 v Reader 4 | 0.79 |
| Reader 1 v Reader 5 | 0.81 |
| Reader 2 v Reader 3 | 0.96 |
| Reader 2 v Reader 4 | 0.88 |
| Reader 2 v Reader 5 | 0.65 |
| Reader 3 v Reader 4 | 0.92 |
| Reader 3 v Reader 5 | 0.68 |
| Reader 4 v Reader 5 | 0.72 |
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem flortaucipir PET imaging for detection of a pattern of flortaucipir neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. For this analysis, B scores of B2-B3 were considered truth positive, and B scores of B0-B1 were considered truth negative.
| percentage of cases correctly identified | Sensitivity of Flortaucipir vs Autopsy NFT Score B2-B3 | Specificity of Flortaucipir vs Autopsy NFT Score B0-B1 |
|---|---|---|
| Reader 1 | 80.4 (68.2 to 88.7) | 87.5 (52.9 to 97.8) |
| Reader 2 | 67.9 (54.8 to 78.6) | 100.0 (67.6 to 100.0) |
| Reader 3 | 67.9 (54.8 to 78.6) | 87.5 (52.9 to 97.8) |
| Reader 4 | 73.2 (60.4 to 83.0) | 87.5 (52.9 to 97.8) |
| Reader 5 | 85.7 (74.3 to 92.6) | 62.5 (30.6 to 86.3) |
Collected over 9 months after flortaucipir scan, up to a total of 18 months if a subject was re-scanned per protocol. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Analysis Population | 73/156 (46.8%) | 3/156 (1.9%) | 14/156 (9%) |
| Event | Safety Analysis Population |
|---|---|
| acute kidney injuryRenal and urinary disorders | 1/156 |
| malignant neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/156 |
| myocardial infarctionCardiac disorders | 1/156 |
| Event | Safety Analysis Population |
|---|---|
| agitationPsychiatric disorders | 3/156 |
| headacheNervous system disorders | 2/156 |
| myocardial infarctionCardiac disorders | 1/156 |
| vertigoEar and labyrinth disorders | 1/156 |
| diarrhoeaGastrointestinal disorders | 1/156 |
| nauseaGastrointestinal disorders | 1/156 |
| injection site bruisingGeneral disorders | 1/156 |
| fallInjury, poisoning and procedural complications | 1/156 |
| procedural vomitingInjury, poisoning and procedural complications | 1/156 |
| hypomagnesaemiaMetabolism and nutrition disorders | 1/156 |
| Age, Continuous(years) | All Enrolled Cohort |
|---|---|
| Mean | 80.2 ± 12.51 |
| Sex: Female, Male(Participants) | All Enrolled Cohort |
|---|---|
| Female | 86 |
| Male | 70 |
| Ethnicity (NIH/OMB)(Participants) | All Enrolled Cohort |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 136 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Enrolled Cohort |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 11 |
| White | 143 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Enrolled Cohort |
|---|---|
| United States | 151 |
| Australia | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2015, a primary completion of Jun 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 2 years 2 months after primary completion. A results delay was requested in Aug 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir